Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial (Q42245782)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 October 2013

Language	Label	Description	Also known as
English	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial	scientific article published on 17 October 2013

Statements

scholarly article

1 reference

Europe PubMed Central

19 October 2017

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial (English)

1 reference

Europe PubMed Central

19 October 2017

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

6

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

19 October 2017

4

object named as

Stanislas Pol

1 reference

Europe PubMed Central

19 October 2017

12

object named as

Andrzej Horban

1 reference

Europe PubMed Central

19 October 2017

author name string

Zobair Younossi

1

1 reference

Europe PubMed Central

19 October 2017

Francesco Negro

2

1 reference

Europe PubMed Central

19 October 2017

Lawrence Serfaty

3

1 reference

Europe PubMed Central

19 October 2017

Moises Diago

5

1 reference

Europe PubMed Central

19 October 2017

Pietro Andreone

7

1 reference

Europe PubMed Central

19 October 2017

Eric J Lawitz

8

1 reference

Europe PubMed Central

19 October 2017

Stuart Roberts

9

1 reference

Europe PubMed Central

19 October 2017

Roberto Focaccia

10

1 reference

Europe PubMed Central

19 October 2017

Graham R Foster

11

1 reference

Europe PubMed Central

19 October 2017

Isabelle Lonjon-Domanec

13

1 reference

Europe PubMed Central

19 October 2017

Bruce Coate

14

1 reference

Europe PubMed Central

19 October 2017

Ralph DeMasi

15

1 reference

Europe PubMed Central

19 October 2017

Gaston Picchio

16

1 reference

Europe PubMed Central

19 October 2017

James Witek

17

1 reference

Europe PubMed Central

19 October 2017

language of work or name

0 references

publication date

17 October 2013

1 reference

Europe PubMed Central

19 October 2017

1 reference

Europe PubMed Central

19 October 2017

58

1 reference

Europe PubMed Central

19 October 2017

1897-1906

1 reference

Europe PubMed Central

19 October 2017

6

1 reference

Europe PubMed Central

19 October 2017

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Meta-analysis: insulin resistance and sustained virological response in hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Signalling links in the liver: knitting SOCS with fat and inflammation.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in the Mouse Liver through Induction of USP18/UBP43

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

21 January 2018

The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

7 January 2021

based on heuristic

inferred from DOI database lookup

Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

7 January 2021

based on heuristic

inferred from DOI database lookup

IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26437

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.26437

1 reference

Europe PubMed Central

19 October 2017

1 reference

Europe PubMed Central

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42245782&oldid=1939797798"